Eliquis to Be Available on Cost Plus Drugs Platform Starting Sunday

The blood thinner Eliquis will be available on Mark Cuban's Cost Plus Drugs online pharmacy platform starting Sunday. This development could make the drug more affordable for patients. Cost Plus Drugs operates on a model aimed at lowering drug prices. Eliquis is widely used to treat conditions such as atrial fibrillation and deep vein thrombosis. The drug is currently marketed through a partnership between Bristol-Myers Squibb and Pfizer. Its availability on the platform could create competitive pricing during a period when no generic versions of the drug exist. Cost Plus Drugs sells medications at cost plus a 15% markup and a pharmacy fee. This model may particularly ease the financial burden on patients for high-priced brand-name drugs. The inclusion of Eliquis on this platform could increase access to the drug and reduce healthcare expenditures. This is not investment advice.

📊 BMY — Piyasa Yorumu

▼ down · 60%

BMY shares may face pressure following the news that Eliquis is now available on the Cost Plus Drugs platform. This development has the potential to negatively impact the drug's pricing and market share. Technical indicators also point to weakness: RSI at 46 is below the neutral zone, MACD is below its signal line, and the price is trading below both the 20-day and 50-day moving averages. Selling pressure is expected to persist in the near term.

RSI 14

46.5

MACD

-0.20

24h Δ

-1.42%

📊 PFE — Piyasa Yorumu

▼ down · 60%

The news indicates that Eliquis, one of Pfizer's key revenue sources, being offered on a lower-cost platform could intensify price pressure on the drug. Technical indicators already show a weak outlook, with the RSI below 40, the MACD below its signal line, and the price trading below both the 20-day and 50-day moving averages. In the short term, the combination of these factors suggests a high likelihood of continued downward pressure.

RSI 14

39.8

MACD

-0.12

24h Δ

-0.13%

Canlı Grafikler